• Publications
  • Influence
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
BACKGROUND The new protease inhibitors are potent inhibitors of the human immunodeficiency virus (HIV), and in combination with other antiretroviral drugs they may be able to cause profound andExpand
  • 1,688
  • 40
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study
Objectives: Efavirenz is an effective antiretroviral agent, but central nervous system side effects occur commonly, and population (racial) differences in pharmacokinetics and response have beenExpand
  • 622
  • 33
The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation
Getting HIV Under Control Approximately 1 in 300 people infected with HIV are HIV “controllers” who are able to maintain long-term control of the virus without medication and who do not progress toExpand
  • 939
  • 28
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
BACKGROUND Regimens containing three nucleoside reverse-transcriptase inhibitors offer an alternative to regimens containing nonnucleoside reverse-transcriptase inhibitors or protease inhibitors forExpand
  • 510
  • 18
Antiretroviral therapy in a thousand patients with AIDS in Haiti.
BACKGROUND The one-year survival rate of adults and children with the acquired immunodeficiency syndrome (AIDS), without antiretroviral therapy, has been about 30 percent in Haiti. AntiretroviralExpand
  • 304
  • 16
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was largely ineffective in pre-clinical and clinical settings and was therefore abandoned. However, recently developedExpand
  • 444
  • 15
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.
BACKGROUND Efavirenz has a long plasma half-life and a low genetic barrier to resistance. Simultaneously stopping treatment with all agents in efavirenz-containing regimens may result in functionalExpand
  • 226
  • 13
Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo
High-throughput sequencing platforms provide an approach for detecting rare HIV-1 variants and documenting more fully quasispecies diversity. We applied this technology to the V3 loop-coding regionExpand
  • 226
  • 11
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.
T-1249 is a 39-aa synthetic peptide that inhibits fusion of human immunodeficiency virus (HIV) to the host target cell. A 14-day open-label, phase 1/2 dose-escalation monotherapy study of the safetyExpand
  • 118
  • 11
Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.
BACKGROUND For adults with human immunodeficiency virus (HIV) infection who have CD4+ T-cell counts that are greater than 200 and less than 350 per cubic millimeter and who live in areas with limitedExpand
  • 355
  • 10